CN105792820A - 用于治疗眼疾病的cetp调节剂 - Google Patents

用于治疗眼疾病的cetp调节剂 Download PDF

Info

Publication number
CN105792820A
CN105792820A CN201480065543.XA CN201480065543A CN105792820A CN 105792820 A CN105792820 A CN 105792820A CN 201480065543 A CN201480065543 A CN 201480065543A CN 105792820 A CN105792820 A CN 105792820A
Authority
CN
China
Prior art keywords
amd
cetp
neovascularization
lutein
cetp modulator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480065543.XA
Other languages
English (en)
Chinese (zh)
Inventor
埃弗利娜·沙皮
埃里克·J·尼泽尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN105792820A publication Critical patent/CN105792820A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A61J1/035—Blister-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D1/00—Rigid or semi-rigid containers having bodies formed in one piece, e.g. by casting metallic material, by moulding plastics, by blowing vitreous material, by throwing ceramic material, by moulding pulped fibrous material or by deep-drawing operations performed on sheet material
    • B65D1/02—Bottles or similar containers with necks or like restricted apertures, designed for pouring contents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Mechanical Engineering (AREA)
  • Ceramic Engineering (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201480065543.XA 2013-12-19 2014-12-16 用于治疗眼疾病的cetp调节剂 Pending CN105792820A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13198668 2013-12-19
EP13198668.9 2013-12-19
PCT/EP2014/077855 WO2015091410A1 (en) 2013-12-19 2014-12-16 Cetp modulator for use in the treatment of eye disease

Publications (1)

Publication Number Publication Date
CN105792820A true CN105792820A (zh) 2016-07-20

Family

ID=49880487

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480065543.XA Pending CN105792820A (zh) 2013-12-19 2014-12-16 用于治疗眼疾病的cetp调节剂

Country Status (11)

Country Link
US (2) US20160287537A1 (https=)
EP (2) EP3082784A1 (https=)
JP (1) JP6539661B2 (https=)
KR (1) KR20160093024A (https=)
CN (1) CN105792820A (https=)
BR (1) BR112016013923A2 (https=)
CA (1) CA2924401A1 (https=)
HK (1) HK1223827A1 (https=)
MX (1) MX2016005505A (https=)
RU (1) RU2016127357A (https=)
WO (1) WO2015091410A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2978859B1 (en) 2013-03-27 2018-06-27 F.Hoffmann-La Roche Ag Genetic markers for predicting responsiveness to therapy
RU2703192C2 (ru) 2014-07-30 2019-10-15 Ф. Хоффманн-Ля Рош Аг Генетические маркеры для прогнозирования ответа на терапию поднимающими уровень hdl или имитирующими hdl агентами
WO2025093129A1 (en) * 2023-11-01 2025-05-08 Newamsterdam Pharma B.V. Treatment and prevention of age-related macular degeneration using a cetp inhibitor
WO2025093436A1 (en) * 2023-11-01 2025-05-08 Newamsterdam Pharma B.V. Treatment and prevention of age-related macular degeneration using a cetp inhibitor
WO2025146262A1 (en) * 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Obicetrapib for use in the treatment of hemoglobinopathies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120301439A1 (en) * 2011-05-24 2012-11-29 Washington University Inhibition of choroidal neovascularization

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2894445B2 (ja) * 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
DE60318390T2 (de) 2002-01-30 2008-12-18 Dsm Ip Assets B.V. Lutein/zeaxanthin gegen blendung
MXPA05009848A (es) * 2003-03-17 2005-12-06 Japan Tobacco Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia del ester de colesterilo.
US7435849B2 (en) 2005-10-31 2008-10-14 Hoffmann-La Roche Inc. Process for the production of acid chlorides
US8212063B2 (en) 2006-05-10 2012-07-03 Omniactive Health Technologies Limited Xanthophyll composition containing trans, meso-zeaxanthin, trans, R, R-zeaxanthin and trans, R, R-lutein useful for nutrition and health care and a process for its preparation
EP1935867A1 (en) 2006-12-20 2008-06-25 F. Hoffmann-La Roche Ag Process for preparing 1-(2-ethyl-butyl)-cyclohexanecarboxylic acid
WO2009129859A1 (en) 2008-04-24 2009-10-29 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Compositions and methods for maintaining, strengthening, improving, or promoting eye health
US20100159029A1 (en) * 2008-12-23 2010-06-24 Alcon Research, Ltd. Composition and nutritional supplements for improving ocular health and reducing ocular inflammatory response
US20110004011A1 (en) 2009-07-01 2011-01-06 Declan Costello Novel process
MY164729A (en) 2010-11-04 2018-01-30 Hoffmann La Roche A composition comprising s-[2- ( [ [1- (2-ethylbutyl) - cyclohexyl] - carbonyl]amino)phenyl] 2-methylpropanethioate and croscarmellose sodium
RU2597793C2 (ru) * 2011-01-25 2016-09-20 Нестек С.А. Способы и композиции для лечения, ослабления или предотвращения ухудшения зрительной системы животных
KR102083700B1 (ko) * 2012-08-21 2020-03-02 옵코 파마슈티칼스, 엘엘씨 리포좀 제제

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120301439A1 (en) * 2011-05-24 2012-11-29 Washington University Inhibition of choroidal neovascularization

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
银娟萍等: "年龄相关性黄斑变性的预防", 《国际眼科杂志》 *

Also Published As

Publication number Publication date
US20160287537A1 (en) 2016-10-06
JP2017500340A (ja) 2017-01-05
EP3524238A1 (en) 2019-08-14
US20190224147A1 (en) 2019-07-25
RU2016127357A (ru) 2018-01-24
HK1223827A1 (zh) 2017-08-11
EP3082784A1 (en) 2016-10-26
MX2016005505A (es) 2016-07-22
WO2015091410A1 (en) 2015-06-25
JP6539661B2 (ja) 2019-07-03
KR20160093024A (ko) 2016-08-05
CA2924401A1 (en) 2015-06-25
BR112016013923A2 (pt) 2017-08-08

Similar Documents

Publication Publication Date Title
US20190224147A1 (en) Cetp modulator for use in the treatement of eye disease
Li et al. Identification of StARD3 as a lutein-binding protein in the macula of the primate retina
Taskintuna et al. Update on clinical trials in dry age-related macular degeneration
EA011864B1 (ru) Применение 4-гидроксифенилретинамида и 4-метоксифенилретинамида для лечения офтальмологических состояний
US20120156202A1 (en) Age related macular degeneration treatment
KR20190034638A (ko) 중추 신경계 장애를 치료하기 위한 벤조에이트 화합물과 탄닌산을 함유하는 조성물
Yang et al. Effect of astaxanthin on metabolic cataract in rats with type 1 diabetes mellitus
CN108685890A (zh) ω脂肪酸用于治疗疾病的用途
Peng et al. Influence/impact of lutein complex (marigold flower and wolfberry) on visual function with early age-related macular degeneration subjects: a randomized clinical trial
CN101252924A (zh) 通过血清视黄醇、血清视黄醇结合蛋白(rbp)和/或血清视黄醇-rbp调节治疗眼部疾病的方法和组合物
FI3897595T3 (en) Nutraceutical ophthalmic composition for treating diseases of the retina with neovascular component
US20170035708A1 (en) Use of n-(4-tert-butylbenzyl)-3-chloro-n-[2-(4-chloro-3-ethyl-phenyl)-ethyl]-2-fluoro-5-trifluoromethyl-benzamide for the treatment of eye diseases
TWI564006B (zh) 包含香葉基香葉基丙酮之眼科用組成物
Renzi et al. Lutein and age-related ocular disorders in the older adult: a review
CN107921077A (zh) 用于治疗年龄相关性黄斑病的草药组合物
US11717513B2 (en) Mirabegron for the treatment of retinal diseases
EP3875092B1 (en) Composition for prevention or treatment of macular degeneration
RU2806096C2 (ru) Нутрицевтическая офтальмологическая композиция для лечения патологий сетчатки с неоваскулярным компонентом
JP5109113B2 (ja) ＩｇＥ捕捉剤、並びに抗アレルギー性の医薬組成物、化粧料組成物、食料組成物、飲料組成物及び飼料組成物
Abraham et al. Age-related macular degeneration and its treatment options
KR20260020540A (ko) 알로에 베라 겔을 포함하는 안구질환 예방 또는 치료용 조성물
CN119792252A (zh) 一种改善年龄相关性黄斑变性的微胶囊产品及其制备方法和应用
TW201542198A (zh) 視網膜疾病之預防、改善或治療劑

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1223827

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160720

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1223827

Country of ref document: HK